Hospital
Bothwell Regional Health Center
Bothwell Regional Health Center was paid $19.78M by Medicaid between Jan 2018 and Dec 2024, across 120 billing codes. Its largest line is 99284, emergency room visit (serious) — 18% of everything it billed.
33Billing provider infoBOTHWELL REGIONAL HEALTH CENTER
SEDALIA, MO 65301
SEDALIA, MO 65301
33aNPI1235102690assigned 02/08/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$19.78M
24GClaims236,584
24DCodes billed120
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Missouri
Rank by total paid#19 of 74
Median peer was paid$4.44M
This provider vs. median4.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 31,717 | $4.92M | |
| 2019 | 31,831 | $5.43M | |
| 2020 | 27,411 | $3.10M | |
| 2021 | 30,841 | $941K | |
| 2022 | 41,739 | $1.88M | |
| 2023 | 43,824 | $2.13M | |
| 2024incomplete | 29,221 | $1.37M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 22,125 | 18,858 | $3.47M |
| X4011 | State-specific procedure code | 16% | 9,964 | 9,289 | $3.23M |
| Y7506 | 14% | 17,708 | 16,146 | $2.70M | |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.2% | 15,922 | 13,374 | $1.82M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 6.8% | 28,591 | 26,336 | $1.35M |
| 80053 | Comprehensive metabolic panel | 6.7% | 27,183 | 25,084 | $1.32M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.2% | 12,718 | 11,980 | $638K |
| 71045 | Radiologic examination, chest; single view | 2.7% | 9,560 | 9,057 | $531K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.6% | 2,458 | 2,127 | $512K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.9% | 2,780 | 2,712 | $385K |
| 36415 | Collection of venous blood by venipuncture | 1.9% | 15,820 | 13,992 | $370K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.7% | 2,257 | 2,220 | $333K |
108 more codes
| 87400 | 1.3% | 1,182 | $250K | |
| 81003 | 1.2% | 4,047 | $239K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.1% | 2,943 | $218K |
| X4006 | 1.0% | 332 | $206K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.0% | 2,227 | $199K |
| 81001 | <1% | 5,960 | $182K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,850 | $147K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,610 | $129K |
| X4003 | <1% | 2,094 | $125K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 855 | $96K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 2,130 | $89K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,908 | $84K |
| 84484 | <1% | 3,595 | $82K | |
| 83690 | <1% | 1,680 | $60K | |
| 87634 | <1% | 531 | $44K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 258 | $43K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 9,016 | $42K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,525 | $37K |
| Y7507 | <1% | 272 | $37K | |
| 95816 | <1% | 296 | $36K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 857 | $35K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 119 | $35K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 289 | $33K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 1,550 | $32K |
| 62323 | <1% | 551 | $31K | |
| 95811 | <1% | 75 | $31K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 176 | $31K |
| 86703 | <1% | 966 | $29K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 449 | $28K |
| 87807 | <1% | 76 | $26K | |
| 86803 | <1% | 813 | $26K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 326 | $23K |
| 85610 | <1% | 1,079 | $22K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 501 | $22K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 880 | $21K |
| 83880 | <1% | 791 | $21K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 120 | $21K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 438 | $20K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 402 | $20K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 384 | $16K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 728 | $16K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 318 | $16K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 83 | $15K |
| 76801 | <1% | 247 | $15K | |
| 80055 | <1% | 197 | $13K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 456 | $10K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 508 | $9K |
| 51798 | <1% | 460 | $8K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 216 | $8K |
| 82962 | <1% | 460 | $8K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 32 | $8K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 145 | $8K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 70 | $8K |
| 87480 | <1% | 152 | $7K | |
| G0378 | Hospital observation service, per hour | <1% | 66 | $7K |
| 87510 | <1% | 148 | $7K | |
| 87660 | <1% | 101 | $7K | |
| 0352U | <1% | 89 | $7K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 61 | $7K |
| 84703 | <1% | 63 | $6K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 75 | $6K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 390 | $6K |
| 87653 | <1% | 130 | $5K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 254 | $4K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 51 | $4K |
| 86850 | <1% | 166 | $3K | |
| 80061 | Lipid panel | <1% | 142 | $3K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 12 | $2K |
| 86762 | <1% | 154 | $2K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 306 | $2K |
| 86592 | <1% | 619 | $2K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 12 | $2K |
| 84439 | <1% | 130 | $2K | |
| 82947 | <1% | 82 | $1K | |
| 87340 | <1% | 155 | $1K | |
| 80047 | <1% | 336 | $1K | |
| 83735 | <1% | 311 | $1K | |
| 77003 | <1% | 12 | $785.80 | |
| 82607 | <1% | 103 | $778.01 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 103 | $626.64 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 12 | $594.09 |
| 80076 | <1% | 235 | $556.03 | |
| 83605 | <1% | 88 | $524.34 | |
| 94060 | <1% | 16 | $517.14 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 26 | $490.82 |
| 87070 | <1% | 65 | $490.45 | |
| 84481 | <1% | 50 | $479.40 | |
| 99072 | <1% | 79 | $474.00 | |
| 97597 | <1% | 31 | $437.58 | |
| 85379 | <1% | 95 | $427.67 | |
| 82310 | <1% | 251 | $416.74 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 25 | $352.02 |
| 82728 | <1% | 75 | $319.22 | |
| 87186 | <1% | 26 | $247.37 | |
| 84145 | <1% | 31 | $243.36 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 12 | $234.96 |
| 94727 | <1% | 16 | $206.74 | |
| 83550 | <1% | 74 | $204.73 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 26 | $201.84 |
| 83540 | <1% | 74 | $151.38 | |
| 94729 | <1% | 16 | $126.79 | |
| 81025 | <1% | 17 | $96.05 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 25 | $72.00 |
| J3490 | Unclassified drugs | <1% | 551 | $70.54 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 146 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 36 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 61 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 43 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDAVIS, SEVEN (CFO)